A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biogen Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 192,500 shares of BIIB stock, worth $37.5 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
192,500
Previous 171,300 12.38%
Holding current value
$37.5 Million
Previous $36.9 Million 20.81%
% of portfolio
0.1%
Previous 0.09%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $4.04 Million - $5.02 Million
21,200 Added 12.38%
192,500 $44.6 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $27.6 Million - $34.9 Million
130,200 Added 316.79%
171,300 $36.9 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $2.63 Million - $3.16 Million
-11,800 Reduced 22.31%
41,100 $10.6 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $26.4 Million - $29.8 Million
-104,300 Reduced 66.35%
52,900 $13.6 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $39.6 Million - $45.8 Million
-144,000 Reduced 47.81%
157,200 $44.8 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $129 Million - $147 Million
-503,100 Reduced 62.55%
301,200 $83.7 Million
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $18.2 Million - $22.1 Million
-72,000 Reduced 8.22%
804,300 $223 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $23.2 Million - $32 Million
-119,300 Reduced 11.98%
876,300 $234 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $23.2 Million - $32 Million
-119,300 Reduced 11.98%
876,300 $234 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $19.2 Million - $22.9 Million
-102,500 Reduced 9.33%
995,600 $203 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $125 Million - $157 Million
642,900 Added 141.23%
1,098,100 $231 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $90.6 Million - $116 Million
404,500 Added 797.83%
455,200 $109 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $14.3 Million - $18.7 Million
50,700 New
50,700 $14.3 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $2.29 Million - $3.45 Million
-9,700 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $12.2 Million - $14.1 Million
-46,200 Reduced 82.65%
9,700 $2.75 Million
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $8.3 Million - $11 Million
-32,100 Reduced 36.48%
55,900 $15 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $30.9 Million - $39.3 Million
-115,100 Reduced 56.67%
88,000 $27.8 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $87.7 Million - $121 Million
-398,500 Reduced 66.24%
203,100 $60.3 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $6.31 Million - $7.07 Million
29,000 Added 5.06%
601,600 $140 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $111 Million - $122 Million
504,800 Added 744.54%
572,600 $134 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $21 Million - $32.9 Million
-97,000 Reduced 58.86%
67,800 $16 Million
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $36.2 Million - $45.9 Million
130,000 Added 373.56%
164,800 $49.6 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $6.96 Million - $9.1 Million
23,700 Added 213.51%
34,800 $12.3 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $2.6 Million - $3.1 Million
10,100 Added 1010.0%
11,100 $3.22 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $260,130 - $367,910
1,000 New
1,000 $274,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.